BioSpace News Archive

FDA authorized the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce comprehensive immune protection through CD4+ and CD8+ T cells to both Spike (S) and Nucleocapsid (N) antigens, as well as generate systemic and mucosal antibodies

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA.

NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share.

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced the pricing of an underwritten initial public offering of 2,660,000 shares of common stock at a public offering price of $10.00 per share for aggregate gross proceeds of $26,600,000 prior to deducting underwriting discounts, commissions, and other offering expenses.

EnginZyme seeks to transform the $5 trillion chemical industry through the use of its enzyme-based platform, which combines the breadth and power of nature with the efficiencies of state-of-the-art chemical processing techniques

Ascensia Diabetes Care, a leading global diabetes care company and the maker of the CONTOUR® range of blood glucose monitoring systems, has once again decided to support the Spare A Rose campaign, organized by Life for a Child, for the fourth consecutive year.

New enterprise, Rentschler ATMP Ltd., is part of continuous innovation at Rentschler Biopharma and supports ongoing strategic international expansion

While many university classes across Canada are being held online, some programs require in-person learning and access to on- and off-campus research and learning facilities.

Immunovia is pleased to invite investors, analysts and media to a teleconference with web presentation on Wednesday, February 17, 2021 at 16:30 pm CET.

Cue Health Inc. announced the results of an independent clinical validation study conducted by Mayo Clinic Laboratories evaluating the accuracy of Cue’s COVID-19 Test in the point-of-care setting against the centralized lab PCR testing model.